|
|
|
|
|
|
Sponsors and Collaborators: |
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00006228 |
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill breast cancer cells.
PURPOSE: Phase II trial to study the effectiveness of trastuzumab plus interleukin-2 in treating patients who have metastatic breast cancer that has not responded to previous trastuzumab therapy.
Condition | Intervention | Phase |
Breast Cancer |
Drug: aldesleukin Drug: trastuzumab |
Phase II |
Genetics Home Reference related topics: | breast cancer |
MedlinePlus related topics: | Breast Cancer Cancer |
ChemIDplus related topics: | Aldesleukin Trastuzumab Interleukin-2 |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Phase II Trial of Anti-Her2 Monoclonal Antibody Trastuzumab (Herceptin) in Combination With Low Dose Interleukin-2 (Proleukin) in Metastatic Breast Cancer Patients Who Have Previously Failed Trastuzumab |
Study Start Date: | January 2001 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1 and 8 and interleukin-2 subcutaneously (SC) on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive interleukin-2 SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
Patients are followed for at least 30 days.
PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed breast cancer
HER2 overexpression 3+ by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)
Unidimensionally measurable disease
The following are not considered measurable:
CNS metastases allowed if all of the following conditions are met:
Hormone receptor status:
PATIENT CHARACTERISTICS:
Age:
Sex:
Menopausal status:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, Illinois | |||||
Central Illinois Hematology Oncology Center | |||||
Springfield, Illinois, United States, 62701 | |||||
Decatur Memorial Hospital Cancer Care Institute | |||||
Decatur, Illinois, United States, 62526 | |||||
Evanston Northwestern Health Care - Evanston Hospital | |||||
Evanston, Illinois, United States, 60201 | |||||
Ingalls Memorial Hospital | |||||
Harvey, Illinois, United States, 60426 | |||||
Oncology/Hematology Associates of Central Illinois, P.C. | |||||
Peoria, Illinois, United States, 61602 | |||||
Louis A. Weiss Memorial Hospital | |||||
Chicago, Illinois, United States, 60640 | |||||
Loyola University Medical Center | |||||
Maywood, Illinois, United States, 60153 | |||||
LaGrange Memorial Hospital | |||||
LaGrange, Illinois, United States, 60525 | |||||
University of Chicago Cancer Research Center | |||||
Chicago, Illinois, United States, 60637-1470 | |||||
United States, Indiana | |||||
Fort Wayne Medical Oncology and Hematology, Incorporated | |||||
Fort Wayne, Indiana, United States, 46885-5099 | |||||
United States, Michigan | |||||
Lakeland Medical Center - St. Joseph | |||||
Saint Joseph, Michigan, United States, 49085 | |||||
United States, New Hampshire | |||||
Norris Cotton Cancer Center at Dartmouth Medical School | |||||
Lebanon, New Hampshire, United States, 03756-0002 | |||||
United States, New York | |||||
James P. Wilmot Cancer Center at University of Rochester Medical Center | |||||
Rochester, New York, United States, 14642 | |||||
United States, Ohio | |||||
Arthur G. James Cancer Hospital - Ohio State University | |||||
Columbus, Ohio, United States, 43210-1240 | |||||
United States, Pennsylvania | |||||
Hillman Cancer Center at University of Pittsburgh Cancer Institute | |||||
Pittsburgh, Pennsylvania, United States, 15236 | |||||
United States, Tennessee | |||||
East Tennessee State University Cancer Center at JCMC | |||||
Johnson City, Tennessee, United States, 37604 |
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute |
National Cancer Institute (NCI) |
Study Chair: | Charles L. Shapiro, MD | Arthur G. James Cancer Hospital & Richard J. Solove Research Institute |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000068150, OSU-99H0192, OSU-9945, NCI-195 |
First Received: | September 11, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00006228 |
Health Authority: | United States: Federal Government |
|
|
|
|
|